Deferasirox pharmacokinetic evaluation in β-thalassaemia paediatric patients.

Sarah AllegraJessica CusatoSilvia De FranciaElisa PirroDavide MassanoAntonio PigaAntonio D'Avolio

Published in: The Journal of pharmacy and pharmacology (2016)

Monitoring plasma deferasirox concentrations appears beneficial for guiding appropriate patient treatment, enhancing effectiveness and minimizing toxicity.

Keyphrases

end stage renal disease
randomized controlled trial
chronic kidney disease
newly diagnosed
systematic review
emergency department
intensive care unit
prognostic factors
oxidative stress